ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/28/201618:16:00Amgen Profit Rises 17%, Guidance Raised--Update
04/28/201616:40:47Current Report Filing (8-k)
04/28/201616:40:00Amgen Profit Rises 17%, Guidance Raised
04/28/201616:33:00Amgen Profit Rises 17%, Guidance Raised
04/28/201616:01:00Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5...
04/26/201619:43:02Statement of Changes in Beneficial Ownership (4)
04/26/201619:40:00Statement of Changes in Beneficial Ownership (4)
04/25/201617:30:00Amgen Announces Webcast Of 2016 First Quarter Financial Results
04/25/201609:00:00Amgen To Participate In The 2016 World Medical Innovation Forum™ O...
04/20/201617:16:04Additional Proxy Soliciting Materials (definitive) (defa14a)
04/20/201617:10:44Additional Proxy Soliciting Materials (definitive) (defa14a)
04/19/201616:07:03Additional Proxy Soliciting Materials (definitive) (defa14a)
04/19/201616:00:00Nplate® (Romiplostim) Study In The Lancet Shows Significant...
04/08/201605:10:00AstraZeneca, Eli Lilly in Final Stage of Testing Alzheimer's...
04/07/201616:08:14Additional Proxy Soliciting Materials (definitive) (defa14a)
04/07/201616:04:40Proxy Statement (definitive) (def 14a)
04/05/201618:40:00FDA Approves Rheumatoid Arthritis Biosimilar -- Update
04/05/201617:50:00FDA Approves Rheumatoid Arthritis Biosimilar
04/05/201617:42:00FDA Approves Rheumatoid Arthritis Biosimilar
04/03/201609:05:00Positive Efficacy And Tolerability Study Of Repatha® (evolocumab...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad